Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 201

1.

ABCG2 Overexpression Contributes to Pevonedistat Resistance.

Kathawala RJ, Espitia CM, Jones TM, Islam S, Gupta P, Zhang YK, Chen ZS, Carew JS, Nawrocki ST.

Cancers (Basel). 2020 Feb 12;12(2). pii: E429. doi: 10.3390/cancers12020429.

2.

Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.

Cai CY, Zhang W, Wang JQ, Lei ZN, Zhang YK, Wang YJ, Gupta P, Tan CP, Wang B, Chen ZS.

Biochem Pharmacol. 2020 Feb 7:113848. doi: 10.1016/j.bcp.2020.113848. [Epub ahead of print]

PMID:
32044354
3.

Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.

Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR Jr, Chen ZS, Cheng XD, Qin JJ.

Drug Resist Updat. 2020 Jan 22;49:100681. doi: 10.1016/j.drup.2020.100681. [Epub ahead of print] Review.

PMID:
32014648
4.

Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.

Wei LY, Wu ZX, Yang Y, Zhao M, Ma XY, Li JS, Yang DH, Chen ZS, Fan YF.

Exp Cell Res. 2020 Jan 20:111858. doi: 10.1016/j.yexcr.2020.111858. [Epub ahead of print]

PMID:
31972220
5.

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, Hu C, Liao D, Zhang W, Chen ZS.

Mol Cancer. 2020 Jan 17;19(1):10. doi: 10.1186/s12943-019-1112-1.

6.

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.

7.

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.

Gupta P, Zhang GN, Barbuti AM, Zhang X, Karadkhelkar N, Zhou J, Ding K, Pan J, Yoganathan S, Yang DH, Chen ZS.

Cancer Lett. 2020 Mar 1;472:132-141. doi: 10.1016/j.canlet.2019.11.040. Epub 2019 Dec 11.

PMID:
31837444
8.

Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.

Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ, Cai CY, Vera AA, Zhang L, Chen ZS, Yang DH.

Molecules. 2019 Nov 30;24(23). pii: E4383. doi: 10.3390/molecules24234383.

9.

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.

Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr, Chen ZS.

Drug Resist Updat. 2020 Jan;48:100663. doi: 10.1016/j.drup.2019.100663. Epub 2019 Nov 11. Review.

PMID:
31785545
10.

A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer.

Jiang Y, Guo Z, Fang J, Wang B, Lin Z, Chen ZS, Chen Y, Zhang N, Yang X, Gao W.

Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110224. doi: 10.1016/j.msec.2019.110224. Epub 2019 Oct 14.

PMID:
31761194
11.

Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.

Wang JQ, Wang B, Lei ZN, Teng QX, Li JY, Zhang W, Ji N, Cai CY, Ma LY, Liu HM, Chen ZS.

Eur J Pharmacol. 2019 Nov 15;863:172611. doi: 10.1016/j.ejphar.2019.172611. Epub 2019 Aug 30.

PMID:
31476282
12.

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells.

Cui Q, Cai CY, Wang JQ, Zhang S, Gupta P, Ji N, Yang Y, Dong X, Yang DH, Chen ZS.

Int J Mol Sci. 2019 Aug 22;20(17). pii: E4095. doi: 10.3390/ijms20174095.

13.

Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.

Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X, Lei ZN, Hettinghouse A, Liu J, Wang C, Zhang C, Bi Y, Xiao G, Chen ZS, Liu CJ.

Ann Rheum Dis. 2019 Nov;78(11):1524-1535. doi: 10.1136/annrheumdis-2019-215543. Epub 2019 Jul 13.

PMID:
31302596
14.

Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.

Cai CY, Zhai H, Lei ZN, Tan CP, Chen BL, Du ZY, Wang JQ, Zhang YK, Wang YJ, Gupta P, Wang B, Chen ZS.

Eur J Med Chem. 2019 Oct 1;179:849-862. doi: 10.1016/j.ejmech.2019.06.066. Epub 2019 Jun 24.

PMID:
31302589
15.

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study.

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D.

Front Oncol. 2019 Jun 18;9:514. doi: 10.3389/fonc.2019.00514. eCollection 2019.

16.

Revisiting mTOR inhibitors as anticancer agents.

Teng QX, Ashar YV, Gupta P, Gadee E, Fan YF, Reznik SE, Wurpel JND, Chen ZS.

Drug Discov Today. 2019 Oct;24(10):2086-2095. doi: 10.1016/j.drudis.2019.05.030. Epub 2019 Jun 4. Review.

PMID:
31173912
17.

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.

Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS.

Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. eCollection 2019.

18.

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS.

Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9.

PMID:
31078601
19.

Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.

Mol Pharmacol. 2019 Jul;96(1):73-89. doi: 10.1124/mol.118.114801. Epub 2019 May 1.

PMID:
31043459
20.

The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo.

Wen Y, Zhao R, Gupta P, Fan Y, Zhang Y, Huang Z, Li X, Su Y, Liao L, Xie YA, Yang D, Chen ZS, Liang G.

Acta Pharm Sin B. 2019 Mar;9(2):316-323. doi: 10.1016/j.apsb.2018.10.001. Epub 2018 Oct 12.

Supplemental Content

Loading ...
Support Center